This 2019 review by Dr. George J. Brewer posits that the rise in Alzheimer’s disease (AD) in developed countries correlates with increased ingestion of divalent copper (Cu²⁺), primarily from copper plumbing and dietary supplements. The author argues that while humans have evolved mechanisms to safely process monovalent copper (Cu¹⁺) from
This article reports on two randomized, double-blind, placebo-controlled Phase 3 trials evaluating bapineuzumab, a humanized monoclonal antibody targeting β-amyloid, in patients with mild-to-moderate Alzheimer’s disease (AD). One trial enrolled APOE ε4 carriers, and the other enrolled noncarriers. Despite some biomarker changes—such as reduced cerebrospinal fluid phosphorylated tau levels and stabilization
This 2014 review examines the role of Toll-like receptors (TLRs) in the pathogenesis of Alzheimer’s disease (AD) and the therapeutic potential of modulating TLR signaling. TLRs are pattern recognition receptors involved in innate immunity, and their dysregulation in AD contributes to chronic neuroinflammation and neuronal damage. The article discusses how
This review investigates cotinine, a non-toxic metabolite of nicotine, as a potential treatment for Alzheimer’s disease (AD). Preclinical studies have shown that cotinine enhances memory, reduces amyloid-beta (Aβ) pathology, and mitigates tau-related neurotoxicity in animal models. Mechanistically, cotinine appears to modulate α7 nicotinic acetylcholine receptors (α7nAChRs), activate the Akt signaling
This study investigates the neuroprotective effects of progesterone (PG) against amyloid-beta (Aβ42)-induced neuroinflammation in astrocytes. The findings reveal that Aβ42 impairs autophagic processes in astrocytes, leading to increased inflammatory responses. Treatment with PG significantly enhances autophagy activation, as evidenced by upregulation of autophagy markers and modulation of the mTOR signaling
This review explores quercetin’s neuroprotective mechanisms in Alzheimer’s disease (AD). Quercetin, a flavonoid with antioxidant properties, mitigates oxidative stress by scavenging reactive oxygen species and modulates signaling pathways such as Nrf2, JNK, MAPK, and PI3K/Akt. These actions reduce neuroinflammation, inhibit amyloid-beta aggregation, and prevent tau hyperphosphorylation. Additionally, quercetin influences gene
This 2019 opinion article by Matt Kaeberlein and Veronica Galvan advocates for initiating clinical trials to assess rapamycin’s efficacy in treating Alzheimer’s disease (AD). Despite compelling preclinical evidence demonstrating rapamycin’s benefits in animal models—such as reducing amyloid-beta and tau pathology, improving cognitive function, and enhancing synaptic plasticity—no human trials had
This review introduces the “endotoxin hypothesis” of Alzheimer’s disease (AD), proposing that elevated levels of lipopolysaccharide (LPS)—an endotoxin from Gram-negative bacteria—play a significant role in AD pathogenesis. The article discusses how LPS can enter the bloodstream from gut dysbiosis or infections and accumulate in the brain, promoting amyloid-beta (Aβ) production,
The article titled “Substantiation for the Use of Curcumin during the Development of Neurodegeneration after Brain Ischemia” (International Journal of Molecular Sciences, 2020, PMID: 31947633) is a review that explores the potential neuroprotective effects of curcumin in the context of brain ischemia. It highlights curcumin’s antioxidant, anti-inflammatory, and anti-apoptotic properties,
This study investigates the effects of methylene blue (MB) in a mouse model of Alzheimer’s disease (AD) induced by neuroinflammation. The study found that MB treatment reduced amyloid beta (Aβ) oligomers, decreased oxidative stress, and improved mitochondrial function by inhibiting the mitochondrial enzyme ABAD. Additionally, MB treatment restored brain estradiol
